DiaMedica ReMEDy2 stroke trial hits 75% enrollment milestone for interim analysis

• DiaMedica Therapeutics reported that its Phase 2/3 ReMEDy2 trial of DM199 in acute ischemic stroke passed 75% of the enrollment needed to trigger a planned interim analysis.
• Results have not been presented yet; the interim review is expected to be completed before year-end 2026.
• The analysis is intended to guide the path forward by determining whether the study should expand enrollment or stop early if the treatment is unlikely to show benefit.
• The trial’s final enrollment target will be set following the interim review, with the company remaining blinded to the underlying findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605200830BIZWIRE_USPR_____20260520_BW356575) on May 20, 2026, and is solely responsible for the information contained therein.